Vitaco: Shanghai Pharmaceuticals, Primavera's $239M Buyout Of Australia's Vitaco Gets FIRB Approval

A US$239 million deal led by Chinese drugmaker Shanghai Pharmaceuticals Holding Co., Ltd. and private equity firm Primavera Capital to acquire Australian vitamins maker Vitaco Holdings has won approval from Australia's Foreign Investment Review Board (FIRB), clearing a major roadblock and pushing the deal closer to completion. In August, the Chinese group said it would [...]Visit ChinaMoneyNetwork.com for more daily finance news, including audio and video Internet podcasts covering important investment news and financial events in China. Follow us on Twitter @chinamoneypod subscribe to all episodes on iTunes.